argenx SE (ARGX.BR)
EUR 531.0
(-0.11%)
EUR 531.0
(-0.11%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -199.5 Million EUR | 54.64% |
| 2022 | -610.48 Million USD | -131.9% |
| 2021 | -344.12 Million USD | 41.75% |
| 2020 | -536.23 Million EUR | -180.68% |
| 2019 | -177.81 Million EUR | -104.34% |
| 2018 | -93.06 Million EUR | -233.69% |
| 2017 | -28.02 Million EUR | -21.19% |
| 2016 | -21.68 Million EUR | -31.88% |
| 2015 | -16.52 Million EUR | -31.62% |
| 2014 | -10.67 Million EUR | -55.72% |
| 2013 | -8.17 Million EUR | 34.93% |
| 2012 | -9.86 Million EUR | -197.57% |
| 2011 | -4.2 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -6.52 Million EUR | 32.15% |
| 2024 Q1 | -54.52 Million USD | -22.33% |
| 2023 Q3 | -50.53 Million USD | 38.11% |
| 2023 Q1 | -87.15 Million USD | 13.28% |
| 2023 Q2 | -81.65 Million USD | 6.31% |
| 2023 FY | - EUR | 54.64% |
| 2023 Q4 | -112.74 Million USD | -123.08% |
| 2022 FY | - USD | -131.9% |
| 2022 Q3 | -200.63 Million USD | -18.27% |
| 2022 Q4 | -100.5 Million USD | 49.9% |
| 2022 Q1 | -221.9 Million USD | -9.71% |
| 2022 Q2 | -169.63 Million USD | 23.56% |
| 2021 Q1 | 6.49 Million EUR | 102.88% |
| 2021 FY | - USD | 41.75% |
| 2021 Q2 | 84.69 Million USD | 1203.2% |
| 2021 Q3 | -212.15 Million USD | -350.49% |
| 2021 Q4 | -202.26 Million USD | 4.66% |
| 2020 Q4 | -225.56 Million EUR | 0.0% |
| 2020 FY | - EUR | -180.68% |
| 2020 Q2 | -209.42 Million EUR | 0.0% |
| 2019 Q1 | -17.46 Million EUR | 61.33% |
| 2019 FY | - EUR | -104.34% |
| 2019 Q4 | -72.76 Million EUR | -104.82% |
| 2019 Q3 | -35.52 Million EUR | 24.87% |
| 2019 Q2 | -47.28 Million EUR | -170.75% |
| 2018 Q2 | -11.05 Million EUR | 34.41% |
| 2018 Q3 | -37.29 Million EUR | -237.43% |
| 2018 FY | - EUR | -233.69% |
| 2018 Q1 | -16.84 Million EUR | -17.08% |
| 2018 Q4 | -45.17 Million EUR | -21.14% |
| 2017 Q1 | -8.97 Million EUR | -6.66% |
| 2017 Q2 | 1.25 Million EUR | 114.01% |
| 2017 Q4 | -14.39 Million EUR | -176.32% |
| 2017 Q3 | -5.2 Million EUR | -514.21% |
| 2017 FY | - EUR | -21.19% |
| 2016 Q3 | -5.91 Million EUR | -23.1% |
| 2016 Q1 | -3.32 Million EUR | 37.42% |
| 2016 FY | - EUR | -31.88% |
| 2016 Q2 | -4.8 Million EUR | -44.4% |
| 2016 Q4 | -8.41 Million EUR | -42.22% |
| 2015 Q2 | -4.6 Million EUR | -25.41% |
| 2015 FY | - EUR | -31.62% |
| 2015 Q4 | -5.31 Million EUR | -57.18% |
| 2015 Q3 | -3.38 Million EUR | 26.54% |
| 2015 Q1 | -3.67 Million EUR | 12.7% |
| 2014 Q2 | -3.7 Million EUR | -43.61% |
| 2014 Q3 | -2.32 Million EUR | 37.21% |
| 2014 Q4 | -4.2 Million EUR | -80.81% |
| 2014 FY | - EUR | -55.72% |
| 2014 Q1 | -2.58 Million EUR | -34.75% |
| 2013 Q2 | -3.93 Million EUR | -64.1% |
| 2013 Q3 | -30.32 Thousand EUR | 99.23% |
| 2013 Q4 | -1.91 Million EUR | -6214.01% |
| 2013 Q1 | -2.39 Million EUR | 0.0% |
| 2013 FY | - EUR | 34.93% |
| 2012 FY | - EUR | -197.57% |
| 2011 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nicox S.A. | -16.23 Million EUR | -1128.636% |
| European Medical Solutions | 59 Thousand EUR | 338245.692% |
| FERMENTALG | -10.51 Million EUR | -1798.249% |
| BioSenic S.A. | -6.79 Million EUR | -2835.638% |
| Celyad Oncology SA | -7.76 Million EUR | -2469.96% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -1231.815% |
| Onward Medical N.V. | -35.23 Million EUR | -466.231% |
| Oxurion NV | -16.72 Million EUR | -1092.576% |
| PHAXIAM Therapeutics S.A. | -22.93 Million EUR | -770.065% |
| Financière de Tubize SA | 184.57 Thousand EUR | 108191.714% |
| UCB SA | 1.26 Billion EUR | 115.722% |